Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
NCT07226206Phase 2Recruiting
- Sponsor
- Roche
- Start
- Sep 2026
- Primary completion
- Apr 2032
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of dirloctocogene samoparvovec in hemophilia A, sponsored by Roche. Started Sep 2026; status: recruiting.
02
Drugs
dirloctocogene samoparvovec
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT07226206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226206.